Ascelia Pharma: Just about to submit Orviglance for US approval - Redeye
Ascelia’s two most important value drivers are the US submission, which is now de-risked, and Ascelia is expecting a submission in early September. The second critical value driver is to secure a US partner for the upcoming launch.
ANNONS
Ascelia’s two most important value drivers are the US submission, which is now de-risked, and Ascelia is expecting a submission in early September. The second critical value driver is to secure a US partner for the upcoming launch.